

**Table 1. Experimental studies examining the role of ferroptosis in liver fibrosis.**

Author(s)	Year	Model	Fibrogenic marker(s)	Compound/target	Effect(s)
Yu et al. <sup>57</sup>	2020	CCL4-induced fibrosis	Masson's trichrome	Slc39a14	Induction of HSC ferroptosis
Sui et al. <sup>60</sup>	2018	CCL4-induced fibrosis	$\alpha$ -SMA, collagen type 1	MgIG	Induction of HSC ferroptosis
Zhang et al. <sup>63</sup>	2018	BDL-treated fibrosis	ACTA2, collagen type 1	ELAVL1	Activation of HSC ferritinophagy/ferroptosis
Kong et al. <sup>59</sup>	2019	CCL4-induced fibrosis	$\alpha$ -SMA, collagen type 1, fibronectin	Artesunate	Activation of HSC ferritinophagy/ferroptosis
Wang et al. <sup>61</sup>	2019	CCL4-induced fibrosis	$\alpha$ -SMA, collagen type 1, fibronectin	Artemether	Induction of HSC ferroptosis
Zhang et al. <sup>62</sup>	2020	BDL-treated fibrosis	ACTA2, collagen type 1	ZFP36	Inhibition of HSC autophagy/ferroptosis
Zhang et al. <sup>64</sup>	2020	BDL-treated fibrosis	HA, LN, PC III, IV-C	BRD7	Induction of HSC ferroptosis

*Abbreviations:* ACTA2, actin alpha 2; CCL4, carbon tetrachloride; MgIG, magnesium isoglycyrrhizinate; HSC, hepatic stellate cells;  $\alpha$ -SMA, alpha-smooth muscle actin; BDL, bile ductligation; ELAVL1, ELAV like RNA-binding protein 1; HA, hyaluronic acid; LN, laminin; PC III, procollagen type III; IV-C, IV- collagen; IRP2, iron regulatory protein 2; BRD7, bromodomain-containing protein 7.